Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-FSTL1 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Pharma Foods International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
The anti-FSTL1 monoclonal antibody is an investigational biologic therapeutic developed by Pharma Foods International using its proprietary ALAgenе® antibody technology platform. It specifically targets Follistatin-like 1 (FSTL1), an extracellular glycoprotein that is often upregulated in the tumor microenvironment and involved in immune dysfunction and cancer progression. The antibody functions by blocking the FSTL1-DIP2A axis, which has been shown in preclinical models to enhance anti-tumor immunity and suppress cancer metastasis. Research indicates potential efficacy across various malignancies, including osteosarcoma and lung cancer, particularly in tumor models with increased mesenchymal stromal/stem cells (MSCs).
- Other names
- FSTL1-monoclonal antibodyFSTL-1-monoclonal antibodyFSTL 1-monoclonal antibodyanti-Follistatin-like 1 monoclonal antibodyanti-Follistatin-like1 monoclonal antibodyanti-Follistatin-like-1 monoclonal antibody
02
Targets
FSTL1 (Follistatin-like protein 1)
Beyond the preview
Go deeper on anti-FSTL1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-FSTL1 monoclonal antibody.